ONC (BeOne Medicines) PE Ratio without NRI: 27.97 (As of Jun. 28, 2026) — 60% Below Median


ONC BeOne Medicines Ltd ONC
81 GF Score
Price $280.00
GF Value $366.06
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BeOne Medicines PE Ratio without NRI?

BeOne Medicines ONC +1.65% 81 PE Ratio without NRI is 27.97 as of Jun. 28, 2026, which is 60% below its 10-year median of 70.32. GuruFocus rates ONC with a GF Score™ of 81/100 and a GF Value™ of $366.06 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 268 Biotechnology companies, BeOne Medicines ranks worse than 56.34% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-06-28), BeOne Medicines's share price is $280.00. BeOne Medicines's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $10.01. Therefore, BeOne Medicines's PE Ratio without NRI for today is 27.97.

During the past 13 years, BeOne Medicines's highest PE Ratio without NRI was 518.52. The lowest was 26.42. And the median was 70.32.

BeOne Medicines's EPS without NRI for the three months ended in Mar. 2026 was $3.25. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $10.01.

As of today (2026-06-28), BeOne Medicines's share price is $280.00. BeOne Medicines's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $4.29. Therefore, BeOne Medicines's PE Ratio (TTM) for today is 65.27.

Good Sign:

BeOne Medicines Ltd stock PE Ratio (=65.27) is close to 1-year low of 61.65.

During the past years, BeOne Medicines's highest PE Ratio (TTM) was 938.00. The lowest was 61.65. And the median was 144.40.

BeOne Medicines's EPS (Diluted) for the three months ended in Mar. 2026 was $1.95. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $4.29.

BeOne Medicines's EPS (Basic) for the three months ended in Mar. 2026 was $2.08. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $4.81.


BeOne Medicines  (NAS:ONC) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


BeOne Medicines PE Ratio without NRI Related Terms


BeOne Medicines PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines PE Ratio without NRI Chart

BeOne Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss 37.69

BeOne Medicines Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 523.40 98.00 74.88 37.69 29.67

ONC vs RVMD, RPRX, BNTX: PE Ratio without NRI Comparison

For the Biotechnology subindustry, BeOne Medicines's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeOne Medicines PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's PE Ratio without NRI falls into.


ONC
81GF Score
BeOne Medicines Ltd ONC
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeOne Medicines PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

BeOne Medicines's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=280.00/10.010
=27.97

BeOne Medicines's Share Price of today is $280.00.
BeOne Medicines's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 27.97 mean?
BeOne Medicines (ONC) has a PE Ratio without NRI of 27.97 as of Jun. 28, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on BeOne Medicines and its competitors. This is 60% below median its historical median of 70.32. Over the past decade, BeOne Medicines' PE Ratio without NRI has ranged from 26.42 to 518.52. According to the industry distribution chart, BeOne Medicines ranks #151 out of 268 companies in the Biotechnology industry, placing it in the top 56.3%.
Is BeOne Medicines' PE Ratio without NRI too high?
BeOne Medicines' current PE Ratio without NRI of 27.97 is 60% below median its 10-year median of 70.32. Over the past 10 years, this metric has ranged from a low of 26.42 to a high of 518.52. The Biotechnology industry median PE Ratio without NRI is 24.35. BeOne Medicines' value of 27.97 is 14.9% above this industry median. Based on the distribution chart, BeOne Medicines ranks #151 out of 268 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BeOne Medicines has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' PE Ratio without NRI compare to RVMD and RPRX?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #151 out of 268 companies for PE Ratio without NRI. This places BeOne Medicines in the lower half of its industry. The industry median PE Ratio without NRI is 24.35. BeOne Medicines' value of 27.97 is 14.9% above this benchmark. Historically, BeOne Medicines' own PE Ratio without NRI has ranged from 26.42 to 518.52 over the past decade. While the company's 10-year median is 70.32 vs. the industry median of 24.35, BeOne Medicines has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Biotechnology company?
The median PE Ratio without NRI among Biotechnology companies is 24.35, based on 268 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BeOne Medicines's current PE Ratio without NRI of 27.97 is 14.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on BeOne Medicines and its competitors. For the Biotechnology industry, the median PE Ratio without NRI is 24.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeOne Medicines's current PE Ratio without NRI is 27.97, which is 60% below median its own 10-year median of 70.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Modestly Undervalued. The stock's GF Value™ is $366.06, compared to a current price of $280.00 — trading 23.5% below its estimated fair value. The current PE Ratio without NRI is 27.97, which is 60% below median its 10-year median of 70.32 and 14.9% above the Biotechnology industry median of 24.35. BeOne Medicines' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For BeOne Medicines (ONC), the current PE Ratio without NRI is 27.97 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (ONC) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of $280.00 is trading 23.5% below its estimated GF Value™ of $366.06. GuruFocus considers BeOne Medicines to be Modestly Undervalued.

Key valuation signals for ONC:

  • PE Ratio without NRI: 27.97 (60% below median its 10-year median of 70.32)
  • GF Value™: $366.06 vs. price of $280.00 (23.5% below fair value)
  • GF Score™: 81/100 with 4 warning signs
  • Industry Position: 14.9% above the Biotechnology median (#151 of 268)

No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
81GF Score

Get the complete analysis for ONC

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$280.00
Price
$366.06
GF Value